Artemisinic Acid Market Size, Share & Trends Analysis Report By Type (Antimalarial Injections, Antimalarial Tablets), By Region, And Segment Forecasts, 2023 - 2030

Artemisinic Acid Market Size, Share & Trends Analysis Report By Type (Antimalarial Injections, Antimalarial Tablets), By Region, And Segment Forecasts, 2023 - 2030


Artemisinic Acid Market Growth & Trends


The global artemisinic acid market size is expected to reach USD 975.05 million by 2030, expanding at 4.24% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the high burden of malaria in underdeveloped and developing economies, a large number of research studies concerning Malaria, and initiatives by public organizations such as the WHO, UNICEF, and others. These organizations are committed to controlling the incidences of malaria globally by creating awareness about malaria treatment.

Developing and underdeveloped economies suffer from a high burden of malaria. For instance, as per UNICEF, malaria is a major cause of death among children in Africa. The WHO states that 95% of total malaria cases were reported in Africa region. The high burden of diseases in this region is expected to boost the demand for artemisinic acid, especially in these regions, and thus boost the market.

Public organizations globally are trying to reduce the incidence of malaria by improving access to detection, treatment, and prevention of the disease. Moreover, organizations such as WHO, UNICEF, the government organization are actively involved in raising awareness about malaria treatment to reduce the spread of the infection. This is expected to improve the demand for artemisinic acid during the forecast period.

The Global Fund states that there was a fall in malaria diagnosis and treatment in 2020 as compared to the previous year. This is because the majority of diagnosis was done for testing COVID-19. This initially hampered the market of artemisinic acid. However, World Malaria Report states that malaria incidences totaled 247 million in 2021, whereas in 2020, the figure stood at 245 million. The increase in the incidence of malaria is expected to boost the demand for malaria treatments and boost the market in the post-pandemic period.

Artemisinic Acid Market Report Highlights

  • The antimalarial tablet segment is expected to grow at the fastest rate of 4.26% CAGR, owing to the high preference for tablet formulation as it provides ease of administration and does not rely on professional assistance
  • Asia Pacific region is expected to grow at a rate of 4.13% CAGR over the forecast owing to the surge in the number of initiatives by the public organization to increase awareness about malaria treatments
  • MEA region held the largest share of 56.89% in 2022, owing to the high burden of malaria in the region, thus contributing to the demand for treatment
Please note The report will be delivered in 3-8 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Artemisinic Acid Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. High prevalence of Malaria
3.3.1.2. Initiatives by public organizations to improve access to malaria treatment
3.3.1.3. High adoption of Artemisinin-based combination therapies (ACT)
3.3.2. Market restraint analysis
3.3.2.1. Drug resistance with Artemisinin-based combination therapies (ACT)
3.3.2.2. Availability of Substitutes
3.3.3. Covid-19 Impact & Recovery Analysis
3.3.4. Industry Analysis - Porter’s
3.3.5. PESTLE Analysis
Chapter 4. Artemisinic Acid Market: Type Segment Analysis
4.1. Artemisinic Acid Market: Definition & Scope
4.2. Artemisinic Acid Market: Product Market Share Analysis, 2022 & 2030
4.3. Antimalarial Injections
4.3.1. Antimalarial Injections Market, 2018 - 2030 (USD Million)
4.4. Antimalarial Tablets
4.4.1. Antimalarial Tablets Market, 2018 - 2030 (USD Million)
Chapter 5. Artemisinic Acid Market: Regional Analysis
5.1. Artemisinic Acid Regional market share analysis, 2022 & 2030
5.2. North America
5.2.1. North America Market estimates and forecast, 2018 - 2030
5.2.2. U.S.
5.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
5.2.3. Canada
5.2.3.1. Canada Market estimates and forecast, 2018 - 2030
5.3. Europe
5.3.1. Europe Market estimates and forecast, 2018 - 2030
5.3.2. U.K.
5.3.2.1. U.K. Market estimates and forecast, 2018 - 2030
5.3.3. Germany
5.3.3.1. Germany Market estimates and forecast, 2018 - 2030
5.3.4. France
5.3.4.1. France Market estimates and forecast, 2018 - 2030
5.3.5. Italy
5.3.5.1. Italy Market estimates and forecast, 2018 - 2030
5.3.6. Spain
5.3.6.1. Spain Market estimates and forecast, 2018 - 2030
5.3.7. Denmark
5.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
5.3.8. Sweden
5.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
5.3.9. Norway
5.3.9.1. Norway Market estimates and forecast, 2018 - 2030
5.4. Asia Pacific
5.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
5.4.2. China
5.4.2.1. China Market estimates and forecast, 2018 - 2030
5.4.3. India
5.4.3.1. India Market estimates and forecast, 2018 - 2030
5.4.4. Japan
5.4.4.1. Japan Market estimates and forecast, 2018 - 2030
5.4.5. South Korea
5.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
5.4.6. Thailand
5.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
5.4.7. Australia
5.4.7.1. Australia Market estimates and forecast, 2018 - 2030
5.4.8. Pakistan
5.4.8.1. Pakistan Market estimates and forecast, 2018 - 2030
5.4.9. Indonesia
5.4.9.1. Indonesia Market estimates and forecast, 2018 - 2030
5.4.10. Vietnam
5.4.10.1. Vietnam Market estimates and forecast, 2018 - 2030
5.5. Central & South America
5.5.1. Central & South America Market estimates and forecast, 2018 - 2030
5.5.2. Brazil
5.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
5.5.3. Mexico
5.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
5.5.4. Argentina
5.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
5.5.5. Colombia
5.5.5.1. Colombia Market estimates and forecast, 2018 - 2030
5.6. MEA
5.6.1. MEA Market estimates and forecast, 2018 - 2030
5.6.2. South Africa
5.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
5.6.3. Saudi Arabia
5.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
5.6.4. UAE
5.6.4.1. UAE Market estimates and forecast, 2018 - 2030
5.6.5. Kuwait
5.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030
5.6.6. Nigeria
5.6.6.1. Nigeria Market estimates and forecast, 2018 - 2030
5.6.7. Democratic Republic of Congo
5.6.7.1. The Democratic Republic of Congo Market estimates and forecast, 2018 - 2030
5.6.8. Mali
5.6.8.1. Mali Market estimates and forecast, 2018 - 2030
5.6.9. Uganda
5.6.9.1. Uganda Market estimates and forecast, 2018 - 2030
5.6.10. Kenya
5.6.10.1. Kenya Market estimates and forecast, 2018 - 2030
Chapter 6. Competitive Analysis
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Participant Categorization
6.3. Heat-Map Analysis
6.3.1. Artemisinic Acid share analysis
Chapter 7. Competitive Landscape
7.1. Company Profiles
7.1.1. Sanofi
7.1.1.1. Company overview
7.1.1.2. Financial performance
7.1.1.3. Product benchmarking
7.1.1.4. Strategic initiatives
7.1.2. KPC Pharmaceuticals, Inc
7.1.2.1. Company overview
7.1.2.2. Financial performance
7.1.2.3. Product benchmarking
7.1.2.4. Strategic initiatives
7.1.3. Guilin Pharmaceutical Co., Ltd
7.1.3.1. Company overview
7.1.3.2. Financial performance
7.1.3.3. Product benchmarking
7.1.3.4. Strategic initiatives
7.1.4. Calyx Chemicals and Pharmaceuticals Ltd.
7.1.4.1. Company overview
7.1.4.2. Financial performance
7.1.4.3. Product benchmarking
7.1.4.4. Strategic initiatives
7.1.5. Novartis AG
7.1.5.1. Company overview
7.1.5.2. Financial performance
7.1.5.3. Product benchmarking
7.1.5.4. Strategic initiatives
7.1.6. .Ipca Laboratories Ltd
7.1.6.1. Company overview
7.1.6.2. Financial performance
7.1.6.3. Product benchmarking
7.1.6.4. Strategic initiatives
7.1.7. Cipla Inc.
7.1.7.1. Company overview
7.1.7.2. Financial performance
7.1.7.3. Product benchmarking
7.1.7.4. Strategic initiatives
7.1.8. Shin Poong Pharm Co., Ltd
7.1.8.1. Company overview
7.1.8.2. Financial performance
7.1.8.3. Product benchmarking
7.1.8.4. Strategic initiatives
7.1.9. Rupus Global Limited
7.1.9.1. Company overview
7.1.9.2. Financial performance
7.1.9.3. Product benchmarking
7.1.9.4. Strategic initiatives
7.1.10. AdvacarePharma
7.1.10.1. Company overview
7.1.10.2. Financial performance
7.1.10.3. Product benchmarking
7.1.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings